Abstract
A prospective study was conducted to evaluate azithromycin in combination with pyrimethamine for treatment of acuteToxoplasma encephalitis in patients with AIDS. Of the 14 patients given 75 mg pyrimethamine and 500 mg azithromycin daily for four weeks, eight were evaluable for clinical response. Five responded favorably, one had an intermediate response and two an unfavorable response. Of the nine patients evaluable for radiological response, six responded favorably, and three had an intermediate response. Eleven adverse events occurred in nine patients: rash (n=5), abnormal liver function (n=2), vomiting (n=3) and hypoacousia (n=1). This pilot study suggests that the combination of pyrimethamine and azithromycin may be further investigated and that the optimal dosage of azithromycin has yet to be determined.
Similar content being viewed by others
References
Luft BJ, Remington JS: Toxoplasmic encephalitis in AIDS. Clinical Infectious Diseases 1992, 15: 211–222.
Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Vildé JL: Treatment of central nervous system toxoplasmosis with pyrimethamine-sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous treatment. American Journal of Medicine 1988, 84: 94–100.
Dannemann B, McCutchan JA, Israelski D, Antoniski D, Leport C, Luft B, Nussbaum J, Clumeck N, Morlat P, Chiu J, Vildé JL, Orellana M, Feigal D, Bertok A, Heseltine P, Leedom J, Remington J, andthe California Collaborative Group: Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfonamides. Annals of Internal Medicine 1992, 116: 33–43.
Fernandez-Martin J, Leport C, Morlat P, Meyohas MC, Chauvin JP, Vildé JL: Pyrimethamine-clarithromycin combination for treatment of acuteToxoplasma encephalitis in patients with AIDS. Antimicrobial Agents and Chemotherapy 1991, 35: 2049–2052.
Chang HR, Pechere JC: In vitro effects of four macrolides (roxithromycin, spiramycin, azithromycin [CP-62,993], and A-56268) onToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1988, 32: 524–529.
Derouin F, Almadany R, Chau F, Rouveix B, Pocidalo JJ: Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrobial Agents and Chemotherapy 1992, 35: 997–1001.
Mertens J, Barneveld P, Asin H, Ligtvoet E, Maarten V, Branger T, Hoepelman A: Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. Antimicrobial Agents and Chemotherapy 1992, 36: 1456–1459.
Remington JS, Vildé JL: Clindamycin forToxoplasma encephalitis in AIDS. Lancet 1991, 338: 1142–1143.
Huskinson-Mark J, Araujo FG, Remington JS: Evaluation of the effect of drugs on the cyst form ofToxoplasma gondii. Journal of Infectious Discases 1991, 164: 170–177.
Gladue RP, Bright GM, Isaascon RE, Newborg MF: In vitro and in vivo uptake of azithromycin (CP-62, 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy 1989, 33: 277–282.
Israelski D, Dannemann B, Remington JS: Toxoplasmic encephalitis in patients with AIDS. In: Sande MA, Volberding PA (ed): The medical management of AIDS. WB Saunders, Philadelphia, 1990, p. 241–266.
Swanson DJ, Sung Rj, Fine MJ, Orloff JJ: Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. American Journal of Medicine 1992, 92: 61–68.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Saba, J., Morlat, P., Raffi, F. et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 12, 853–856 (1993). https://doi.org/10.1007/BF02000407
Issue Date:
DOI: https://doi.org/10.1007/BF02000407